[1] 李敏然,刘红磊,郭军雪,等.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的疗效研究.国际病毒学杂志,2013,20:262-265.
[2] 杨彩芳.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的临床观察.中国社区医师(医学专业),2012,14:72-73.
[3] Ogasawara K,Terada T, Katsura T, et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet,2010,25:190-199.
[4] Druyts E,Thorlund K,Wu P, et al. Efficacy and safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis. Clin Infect Dis,2013,56:961-967.
[5] 朱义玲,陈丽,赵卫峰,等.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎疗效观察.实用肝脏病杂志,2012,15:123-125.
[6] Lalezari J,Asmuth D, Casir′ A, et al. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother,2012,56:6372-6378.
[7] Hashemi N,Araya V, Tufail K,et al. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol,2011,3:198-204.
[8] 谢群.慢性乙型肝炎患者HBeAg水平与恩替卡韦长期疗效的相关性分析.中国社区医师,2014,30:33-34.
[9] 姚正钢,邓秋月.小剂量普通干扰素联合利巴韦林治疗失代偿期丙肝肝硬化疗效观察.齐齐哈尔医学院学报,2012,33:1131-1132.
[10] 韦新焕,马丽霞,张晶,等.血清铁蛋白是慢性丙肝患者对聚乙二醇干扰素-α和利巴韦林联合治疗应答不佳的独立预测因素.北京医学,2012,34:1088-1090.
[11] 范文君,侯金林,江家骥,等.应答指导治疗策略下聚乙二醇干扰素α-2a与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的经济学评价.中国药物经济学,2013,2:19-22.
[12] Pattullo V,Heathcote EJ,Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int, 2010, 4: 723-731.
[13] 田豫萍.α-干扰素联合恩替卡韦治疗慢性乙型肝炎的效果观察.中国现代医生,2014,52:22-24.
[14] Aoki YH,Ohkoshi S,Yamagiwa S, et al. Characterization of elevated alanine aminotransferase levels during pegylated-interferon α-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res, 2011, 41: 118-125.
[15] Talal AH, Perlman DC,Des Jarlais DC. Quality of care in patients with chronic hepatitis C virus infection. Ann Intern Med,2011,154: 213-214. |
